Trial Watch (Q24618653)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Trial Watch	scientific article

Statements

scholarly article

0 references

Trial Watch (English)

0 references

6

0 references

Alexander M. M. Eggermont

2

0 references

Laurence Zitvogel

5

0 references

Lorenzo Galluzzi

7

0 references

4

0 references

Erika Vacchelli

1

object named as

Erika Vacchelli

0 references

Wolf Hervé Fridman

3

object named as

Wolf Hervé Fridman

0 references

publication date

1 July 2013

0 references

0 references

2

0 references

7

0 references

e24850

0 references

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Inflammation and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Structure of the chemokine receptor CXCR1 in phospholipid bilayers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Trial watch: Cardiac glycosides and cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Immunogenic cell death in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Resolution of inflammation: the beginning programs the end

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

7 April 2017

Trial Watch: Adoptive cell transfer for anticancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial watch: DNA vaccines for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Harnessing the immune system for the treatment of non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial watch: Peptide vaccines in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial watch: Dendritic cell-based interventions for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial Watch: Immunostimulatory cytokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial Watch: Adoptive cell transfer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial watch: Chemotherapy with immunogenic cell death inducers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Trial Watch: Monoclonal antibodies in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Inflammasomes in carcinogenesis and anticancer immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

The secret ally: immunostimulation by anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Immunocytokines: a novel class of potent armed antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Exploiting antitumor immunity to overcome relapse and improve remission duration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Advanced malignant melanoma: immunologic and multimodal therapeutic strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Cytokines and their relationship to the symptoms and outcome of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Hematopoietic cytokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

3. Cytokines and chemokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Current and future use of hematopoietic growth factors in cancer medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Cytokines in cancer pathogenesis and cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

2. Cytokines and chemokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

27 September 2017

Interstitial dendritic cell guidance by haptotactic chemokine gradients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Tumor-infiltrating lymphocytes and outcome in Merkel cell carcinoma, a virus-associated cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Chemoimmunotherapy as long-term maintenance therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Interleukin 21 impairs tumor immunosurveillance of colitis-associated colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Interleukin-21 in cancer immunotherapy: Friend or foe?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

TP53 and MTOR crosstalk to regulate cellular senescence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

30 May 2018

Clinical uses of GM-CSF, a critical appraisal and update

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Trial watch: Chemotherapy with immunogenic cell death inducers.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Interleukin-21 has activity in patients with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

T-helper-1-cell cytokines drive cancer into senescence

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Hepatitis E vaccine debuts.

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Trial watch: Monoclonal antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.4161%2FONCI.24850

21 January 2018

Hematopoietic stem cell mobilization with G-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

28 November 2018

Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782010

28 November 2018

Prognostic role of serum cytokines in patients with nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SnapShot: cytokines II

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SnapShot: Cytokines IV

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SnapShot: cytokines III

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Keeping IL-2 toxicity at bay

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma cytokine profiles at diagnosis in pediatric patients with non-hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SnapShot: Cytokines I

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematology: Rituximab for follicular lymphoma: maintaining an open mind

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion

1 reference

https://pubmed.ncbi.nlm.nih.gov/24073369

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/ONCI.24850

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24618653&oldid=1419830319"